HRTX
Heron Therapeutics, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Nov. 30, 11:03 AM
    | Wed, Nov. 30, 11:03 AM
  • Fri, Nov. 25, 11:01 AM
    | Fri, Nov. 25, 11:01 AM | 2 Comments
  • Tue, Nov. 8, 5:11 PM
    • Heron Therapeutics (NASDAQ:HRTX): Q3 EPS of -$1.24 misses by $0.07.
    • Cash & cash equivalents of $88.91M
    • Press Release
    | Tue, Nov. 8, 5:11 PM | 1 Comment
  • Fri, Oct. 28, 12:40 PM
    • Cidara Therapeutics (NASDAQ:CDTX) initiated with Buy rating by Cantor Fitzgerald.
    • Ohr Pharmaceuticals (NASDAQ:OHRP) initiated with Buy rating and $10 (223% upside) price target by H.C. Wainwright.
    • Sarepta Therapeutics (NASDAQ:SRPT) initiated with Equal Weight rating and $53 (28% upside) price target by Morgan Stanley.
    • AMAG Pharmaceuticals (NASDAQ:AMAG) initiated with Buy rating and $40 (58% upside) price target by Needham.
    • Nabriva Therapeutics (NASDAQ:NBRV) initiated with Outperform rating and $14 (138% upside) price target by Leerink Swann.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) initiated with Outperform rating and $23 (107% upside) price target by Leerink Swann.
    • Glaukos (NYSE:GKOS) initiated with Outperform rating and $42 (midpoint) (26% upside) price target by Wells Fargo.
    • Calithera Biosciences (NASDAQ:CALA) initiated with Sell rating and $1 (62% downside risk) price target by Citigroup.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (173% upside) price target by Aegis Capital.
    • Clovis Oncology (NASDAQ:CLVS) initiated with Sell rating and $15 (50% downside risk) price target by Chardan Capital.
    • Fulgent Genetics (Pending:FLGT) initiated with Overweight rating and $13 (42% upside) price target by Piper Jaffray. Initiated with Buy rating and $15 (64% upside) price target by BTIG Research.
    • Tabula Rosa Healthcare (Pending:TRHC) initiated with Outperform rating and $17 (38% upside) price target by Wells Fargo.
    • Xenon Pharmaceuticals (NASDAQ:XENE) initiated with Buy rating and $18 (121% upside) price target by Stifel Nicolaus.
    | Fri, Oct. 28, 12:40 PM | 2 Comments
  • Fri, Oct. 7, 11:48 AM
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) initiated with Buy rating and $26 (38% upside) price target by H.C. Wainwright.
    • Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and $22 (54% upside) price target by H.C. Wainwright.
    • Mazor Robotics (NASDAQ:MZOR) initiated with Buy rating and $25 (10% upside) price target by B. Riley.
    • Lipocine (NASDAQ:LPCN) initiated with Buy rating and $25 (350% upside) price target by H.C. Wainwright.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating and $28 (218% upside) price target by Brean Capital.
    • Immunomedics (NASDAQ:IMMU) initiated with Buy rating and $5.50 (113% upside) price target by Jefferies.
    • AmerisourceBergen (NYSE:ABC) initiated with Neutral rating by UBS.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Buy rating and $22 (65% upside) price target by SunTrust Robinson Humphrey.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $6 (92% upside) price target by Cantor Fitzgerald.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) initiated with Buy rating and $17 (94% upside) price target by Cantor Fitzgerald.
    • Heron Therapeutics (NASDAQ:HRTX) initiated with Buy rating and $41 (142% upside) price target by Brean Capital.
    • Zogenix (NASDAQ:ZGNX) initiated with Outperform rating and $17 (64% upside) price target by Leerink Swann.
    • GW Pharmaceuticals (NASDAQ:GWPH) initiated with Outperform rating and $162 (23% upside) price target by Leerink Swann. Initiated with Buy rating and $189 (44% upside) price target by Goldman Sachs.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Outperform rating and $68 (57% upside) price target by Leerink Swann.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $221 (79% upside) price target by Brean Capital.
    • Axsome Therapeutics (NASDAQ:AXSM) initiated with Buy rating and $20 (136% upside) price target by Brean Capital.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (156% upside) price target by Brean Capital.
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $16 (226% upside) price target by Brean Capital.
    • Sorrento Therapeutics (NASDAQ:SRNE) initiated with Buy rating and $15 (94% upside) price target by Roth Capital.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Outperform rating and a $75 - 81 (322% upside from midpoint) target price range by Wells Fargo.
    • Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Buy rating and $45 (49% upside) price target by Brean Capital.
    | Fri, Oct. 7, 11:48 AM | 8 Comments
  • Wed, Oct. 5, 12:46 PM
    | Wed, Oct. 5, 12:46 PM | 2 Comments
  • Sun, Oct. 2, 10:05 PM
    • In a regulatory filing, Heron Therapeutics (NASDAQ:HRTX) reports that three executives have or will be departing in connection with the company's realignment of goals and objectives following the FDA approval of SUSTOL (granisetron).
    • Neil Clendeninn, Ph.D., SVP, Chief Medical Officer and Paul Marshall, SVP, Technical Operations resigned September 30. Brian Drazba, VP, Finance and CFO, will resign effective March 31, 2017.
    | Sun, Oct. 2, 10:05 PM | 17 Comments
  • Tue, Sep. 20, 4:46 PM
    | Tue, Sep. 20, 4:46 PM | 42 Comments
  • Wed, Aug. 10, 11:00 AM
    | Wed, Aug. 10, 11:00 AM | 2 Comments
  • Wed, Aug. 10, 9:25 AM
    • Heron Therapeutics (NASDAQ:HRTX) is up 17% premarket on robust volume in response to its announcement that the FDA has approved SUSTOL (granisetron) extended-release injection for the treatment of acute and delayed chemotherapy-induced nausea and vomiting.
    • SUSTOL's long-acting formulation is based on the company's Biochronomer drug delivery technology which enables granisetron to remain in the body at therapeutic levels for at least five days with a single subcutaneous injection.
    • Read now Heron Therapeutics Has An Upcoming Approval 
    | Wed, Aug. 10, 9:25 AM | 37 Comments
  • Wed, Aug. 10, 9:17 AM
    | Wed, Aug. 10, 9:17 AM | 4 Comments
  • Mon, Aug. 8, 4:41 PM
    • Heron Therapeutics (NASDAQ:HRTX): Q2 EPS of -$1.17 misses by $0.21.
    • Cash and equivalents of $74.6M
    • Press Release
    | Mon, Aug. 8, 4:41 PM
  • Mon, Aug. 1, 10:13 AM
    • Heron Therapeutics (HRTX +11.9%) has announced preliminary, positive, top-line efficacy results from two Phase 2 clinical studies of HTX-011, its lead product candidate for the management of post-operative pain in patients undergoing bunionectomy and inguinal hernia repair.
    • HTX-011 is the first long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam and is designed to target both post-operative pain and its associated inflammation.
    | Mon, Aug. 1, 10:13 AM | 2 Comments
  • Mon, Aug. 1, 10:00 AM
    | Mon, Aug. 1, 10:00 AM
  • Mon, Aug. 1, 9:21 AM
    | Mon, Aug. 1, 9:21 AM | 11 Comments
  • Fri, May 6, 10:32 AM
    • Baxter International (BAX -1.1%) initiated with Buy rating and $51 (13% upside) price target by Evercore ISI.
    • Intrexon (XON +2.3%) initiated with Market Outperform rating and $42 (62% upside) price target by JMP Securities.
    • Heron Therapeutics (HRTX -8.8%) initiated with Buy rating and $41 (143% upside) price target by Cantor Fitzgerald.
    • Dr. Reddy's Laboratories (RDY -2.5%) initiated with Neutral rating and Rs.3,334 price target (8% upside) by Goldman Sachs.
    • Aeglea BioTherapeutics (AGLE +7.4%) initiated with Buy rating and $12 (33% upside) price target by UBS.
    • Cardiome (CRME +34.9%) upgraded to Speculative Buy from Hold by Mackie Research. Price target raised to $8.60 (58% upside) from $5.20.
    • Medivation (MDVN +1.2%) upgraded to Buy from Neutral by Citigroup. Price target raised to $73 (22% upside) from $37.
    • Masimo (MASI -0.3%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $52 (13% upside) from $43.
    • GlaxoSmithKline (GSK -1%) upgraded to Buy from Reduce by Oddo & Cie.
    • Cogentix Medical (CGNT -1%) downgraded to Neutral from Buy with a price target of $1.15 (14% upside) by Roth Capital.
    • Bruker (BRKR +0.8%) downgraded to Neutral from Outperform by BTIG Research.
    • Relypsa (RLYP -4%) downgraded to Underperform from Neutral by Mizuho Securities. Price target cut to $31 (132% upside) from $34.
    • Molina Healthcare (MOH -0.7%) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $45 (0% upside) from $75. Downgraded to Neutral from Buy by UBS. Price target lowered to $54 (20% upside) from $76.
    • Sarepta Therapeutics (SRPT +1.8%) downgraded to Underperform from Market Perform by Leerink Swann. Price target lowered to $5 (71% downside risk) from $13.
    • Sanofi (SNY -0.4%) downgraded to Hold from Buy with an €81 (15% upside) price target by HSBC.
    | Fri, May 6, 10:32 AM | 4 Comments